Overview


According to FutureWise analysis the market for antibodies contract manufacturing in 2023 is US$ 15.41 billion, and is expected to reach US$ 41.9 billion by 2031 at a CAGR of 13.3%.

Antibodies contract manufacturing refers to the outsourcing of the certain antibodies to  third-party service provider. This process involves the development, production, and purification of antibodies for use in various applications, such as diagnostics, therapeutics, and research. CDMOs (Contract Development and Manufacturing Organizations) play an important role in antibody production. Nevertheless, in biopharmaceuticals, the development and manufacturing of drug products is a complex and highly regulated process, which also applies to innovative tools like recombinant antibodies. CDMOs play a vital role in the biopharmaceutical industry by providing end-to-end services for developing and manufacturing biologics, including monoclonal antibodies (mAbs). They offer various services, from process development to large-scale manufacturing, enabling pharma and biopharma companies to outsource their manufacturing needs to a specialized contract development and manufacturing organization.

Monoclonal antibodies are immunoglobulins produced from a single B-cell lineage. These antibodies recognize unique epitopes, or binding sites, on a single antigen. Derivation from a single B-cell clone and subsequent targeting of a single epitope differentiates monoclonal antibodies from polyclonal antibodies. This has become an important tool in different areas including molecular biology, biochemistry, and medicine. The use of monoclonal antibodies to treat disorders is called immunotherapy because each type of monoclonal antibody will target a specific antigen in the body. Monoclonal antibodies are used to treat psoriasis, ulcerative colitis, Crohn's disease, cancer, cardiovascular disease, multiple sclerosis, and rheumatoid arthritis.

FutureWise Market Research has published a report that provides an insightful analysis antibodies contract manufacturing market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, antibodies contract manufacturing market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • AMRI
  • AGC Biologics
  • Aldevron
  • Eurofins CDMO
  • Boehringer Ingelheim BioXcellence
  • FUJIFILM Diosynth Biotechnologies
  • Emergent BioSolutions
  • KBI Biopharma
  • Lonza
  • Novasep
  • Nitto Avecia Pharma Services
  • Pierre Fabre
  • Samsung BioLogics
  • Synthon
  • Thermo Fisher Scientific
  • AbbVie, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Antibodies Contract Manufacturing Market:

  • In May 2023, AbbVie announced the FDA approval of EPKINLYTM, the first and only T-cell-engaging bispecific antibody approved to treat adult patients suffering from R/R (relapsed or refractory) diffuse large B-cell lymphoma. To meet the increased demand for EPKINLYTM, AbbVie partnered with a specialized contract manufacturing organization (CMO) well-known for its expertise in antibody production.

The increasing prevalence of adoption of personalized medicine, characterized by tailored treatments to an individual's unique genetic makeup, is driving the demand for monoclonal antibodies. This demand is attributed to the remarkable specificity and effectiveness of monoclonal antibodies in targeting precise disease markers. Their adaptability to handle various genetic variations makes them indispensable in the era of personalized therapeutics, driving the antibodies contract manufacturing market. Moroever, outsourcing antibody manufacturing offers biopharmaceutical companies a proposition of cost-effective and time-saving production compared to on-site manufacturing. Installing and maintaining a dedicated antibody production facility entails substantial capital investment, including advanced equipment, specialized personnel, and stringent quality control measures. Pharmaceutical companies may shift capital toward core research and development activities by contracting out this process to specialized manufacturers. Thus, with the expertise and advanced infrastructure of contract manufacturers, biopharmaceutical companies improve costs and production timelines to achieve access to a range of product offerings in the target market. However, the production of antibodies involves complex processes, from cell line development to purification and quality assurance. Providing consistently high-quality output is challenging, especially for smaller contract manufacturing organizations. They may often struggle with limited resources and may lack the economies of scale that bigger facilities benefit from. This may present challenges in developing and maintaining advanced equipment and possessing trained personnel. Also, stringent regulatory guidelines require thorough documentation, validation, and compliance, which may further hinder the target market over the forecast period.

By Product

  • Monoclonal Antibodies
  • Antibody Fragments
  • Polyclonal Antibodies

By Expression System

  • Mammalian
  • Microbial
    • Bacteria
    • Yeast

By Company Size

  • Small Antibodies Contract Manufacturing Companies
  • Mid-sized Antibodies Contract Manufacturing Companies
  • Large Antibodies Contract Manufacturing Companies
  • Very Large Antibodies Contract Manufacturing Companies

By Scale of Operation

  • Preclinical Antibodies Contract Manufacturing
  • Clinical Antibodies Contract Manufacturing
  • Commercial Antibodies Contract Manufacturing

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is attributed to the widespread manufacturing of biopharmaceuticals in the region, the high prevalence of chronic diseases., the presence of a substantial number of CDMO/CMO facilities, a growing number of clinical trials, and advanced healthcare systems is anticipated to fuel the target market in the region. In addition, the rise in the demand for antibodies contract manufacturing, reimbursement guidelines, technological advancements, product launches, and state and other laws pertaining to biologics development in the region are expected to significantly propel the antibodies contract manufacturing market over the forecast period in this area.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antibodies Contract Manufacturing Market By Product, By Expression System, By Company Size, By Scale of Operation and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antibodies Contract Manufacturing Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antibodies Contract Manufacturing Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antibodies Contract Manufacturing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antibodies Contract Manufacturing Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Monoclonal Antibodies
        2. Antibody Fragments
        3. Polyclonal Antibodies

  • 8.   Antibodies Contract Manufacturing Market, By Expression System Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Mammalian
        2. Microbial
         2.1. Bacteria
         2.2. Yeast

  • 9.   Antibodies Contract Manufacturing Market, By Company Size Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Small Antibodies Contract Manufacturing Companies
        2. Mid-sized Antibodies Contract Manufacturing Companies
        3. Large Antibodies Contract Manufacturing Companies
        4. Very Large Antibodies Contract Manufacturing Companies

  • 10.   Antibodies Contract Manufacturing Market, By Scale of Operation Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Preclinical Antibodies Contract Manufacturing
        2. Clinical Antibodies Contract Manufacturing
        3. Commercial Antibodies Contract Manufacturing

  • 11.   North America Antibodies Contract Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Antibodies Contract Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Antibodies Contract Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Antibodies Contract Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AMRI
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. AGC Biologics
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Aldevron
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Eurofins CDMO
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Boehringer Ingelheim BioXcellence
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. FUJIFILM Diosynth Biotechnologies
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Emergent BioSolutions
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. KBI Biopharma
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Lonza
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
          10. Novasep
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Nitto Avecia Pharma Services
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Pierre Fabre
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
          13. Samsung BioLogics
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
          14. Synthon
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
          15. Thermo Fisher Scientific
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. AbbVie, Inc.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client

Related Market

Biologics Contract Manufacturing Demand Market

Read More

Medical Device Contract Manufacturing Market

Read More

Vaccine Contract Manufacturing Market

Read More

Biopharmaceutical Contract Manufacturing Market

Read More
Partner

Our Clients